Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 20/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21774143 | 1.00 | QPCT (0.88) | QPCT | |
| SCHEMBL29786920 | 1.00 | QPCT (0.88) | QPCT | |
| SCHEMBL21793362 | 1.00 | QPCT (0.88) | QPCT | |
| SCHEMBL21774263 | 0.89 | QPCT (0.86) | QPCT | |
| SCHEMBL21774315 | 0.89 | QPCT (0.86) | QPCT | |
| SCHEMBL21774289 | 0.89 | QPCT (0.86) | QPCT | |
| SCHEMBL21793408 | 0.88 | QPCT (0.69) | QPCT | |
| SCHEMBL21793361 | 0.87 | QPCT (0.88) | QPCT | |
| SCHEMBL21774168 | 0.87 | QPCT (0.88) | QPCT | |
| SCHEMBL21793363 | 0.87 | QPCT (0.88) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020047360-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-05 | — | — | WO | disclosed |
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RES INST (TW) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | GLUL, GLS2, GLS | QPCT 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.